


PHARMACEUTICAL 2021









PHARMACEUTICAL 2021

Regulus Therapeutics Inc. Rank 211 of 409



The relative strengths and weaknesses of Regulus Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Regulus Therapeutics Inc. compared to the market average is the variable Revenues, increasing the Economic Capital Ratio by 73% points. The greatest weakness of Regulus Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 73% points.

The company's Economic Capital Ratio, given in the ranking table, is -143%, being 211% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	36,730
Cost of Goods Sold	0
Intangible Assets	125
Liabilities, Current	11,578
Liabilities, Non-Current	0
Other Assets	749
Other Compr. Net Income	0
Other Expenses	1,808
Other Liabilities	0
Other Net Income	0
Property and Equipment	0
Research and Development	15,347
Revenues	10,239
Selling, General and Administrative Expense	8,814

Output Variable	Value in 1000 USD
Assets	37,604
Liabilities	11,578
Expenses	25,969
Stockholders Equity	26,026
Net Income	-15,730
Comprehensive Net Income	-15,730
Economic Capital Ratio	-143%